Tags

Type your tag names separated by a space and hit enter

Atorvastatin for the treatment of plaque-type psoriasis.
Pharmacotherapy. 2011 Nov; 31(11):1045-50.P

Abstract

STUDY OBJECTIVE

To explore the efficacy and safety of oral atorvastatin for the treatment of plaque-type psoriasis.

DESIGN

Prospective, randomized, double-blind, placebo-controlled study.

SETTING

University-affiliated psoriasis outpatient clinic in Iran.

PATIENTS

Forty-two patients aged 16-60 years with a diagnosis of acute or chronic plaque-type psoriasis with body surface area (BSA) involvement of greater than 10% were enrolled; 40 completed the study. Intervention. Oral atorvastatin 40 mg/day (20 patients) or placebo (20 patients) was administered for 12 weeks; patients' topical therapies with emollients, keratolytics, and/or class V corticosteroids were continued during the study period.

MEASUREMENTS AND MAIN RESULTS

The Psoriasis Area and Severity Index (PASI) and percentage BSA involvement were used to assess the efficacy of therapy. Mean ± SD baseline PASI scores were 7.42 ± 1.90 and 6.92 ± 1.76 in the atorvastatin and placebo groups, respectively. The primary outcomes were the degree of change in PASI scores and percentage BSA involvement from baseline to week 12. Significant improvement in psoriasis lesions was observed in both the atorvastatin and placebo groups (p<0.001 for both groups). A 75% improvement in PASI score (PASI 75) was achieved in 8 patients (40%) in the atorvastatin group and 7 patients (35%) in the placebo group. However, no statistically significant differences were noted between the two treatment groups in mean PASI score, percentage BSA involvement, and PASI 75. In terms of adverse effects, atorvastatin was well tolerated.

CONCLUSION

Oral atorvastatin 40 mg/day was not associated with therapeutic benefit when given to patients with baseline PASI scores less than 12 who were also treated with standard topical therapies. Additional trials are needed to elucidate the place of statins for the treatment of psoriasis. A larger follow-up study, as well as testing atorvastatin in patients with more intensive disease characterized by high PASI scores, is needed. Studies using higher atorvastatin doses or dose-ranging studies should also be performed.

Authors+Show Affiliations

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22026392

Citation

Faghihi, Toktam, et al. "Atorvastatin for the Treatment of Plaque-type Psoriasis." Pharmacotherapy, vol. 31, no. 11, 2011, pp. 1045-50.
Faghihi T, Radfar M, Mehrabian Z, et al. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy. 2011;31(11):1045-50.
Faghihi, T., Radfar, M., Mehrabian, Z., Ehsani, A. H., & Rezaei Hemami, M. (2011). Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy, 31(11), 1045-50. https://doi.org/10.1592/phco.31.11.1045
Faghihi T, et al. Atorvastatin for the Treatment of Plaque-type Psoriasis. Pharmacotherapy. 2011;31(11):1045-50. PubMed PMID: 22026392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atorvastatin for the treatment of plaque-type psoriasis. AU - Faghihi,Toktam, AU - Radfar,Mania, AU - Mehrabian,Zohre, AU - Ehsani,Amir Hoshang, AU - Rezaei Hemami,Mohsen, PY - 2011/10/27/entrez PY - 2011/10/27/pubmed PY - 2012/2/9/medline SP - 1045 EP - 50 JF - Pharmacotherapy JO - Pharmacotherapy VL - 31 IS - 11 N2 - STUDY OBJECTIVE: To explore the efficacy and safety of oral atorvastatin for the treatment of plaque-type psoriasis. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: University-affiliated psoriasis outpatient clinic in Iran. PATIENTS: Forty-two patients aged 16-60 years with a diagnosis of acute or chronic plaque-type psoriasis with body surface area (BSA) involvement of greater than 10% were enrolled; 40 completed the study. Intervention. Oral atorvastatin 40 mg/day (20 patients) or placebo (20 patients) was administered for 12 weeks; patients' topical therapies with emollients, keratolytics, and/or class V corticosteroids were continued during the study period. MEASUREMENTS AND MAIN RESULTS: The Psoriasis Area and Severity Index (PASI) and percentage BSA involvement were used to assess the efficacy of therapy. Mean ± SD baseline PASI scores were 7.42 ± 1.90 and 6.92 ± 1.76 in the atorvastatin and placebo groups, respectively. The primary outcomes were the degree of change in PASI scores and percentage BSA involvement from baseline to week 12. Significant improvement in psoriasis lesions was observed in both the atorvastatin and placebo groups (p<0.001 for both groups). A 75% improvement in PASI score (PASI 75) was achieved in 8 patients (40%) in the atorvastatin group and 7 patients (35%) in the placebo group. However, no statistically significant differences were noted between the two treatment groups in mean PASI score, percentage BSA involvement, and PASI 75. In terms of adverse effects, atorvastatin was well tolerated. CONCLUSION: Oral atorvastatin 40 mg/day was not associated with therapeutic benefit when given to patients with baseline PASI scores less than 12 who were also treated with standard topical therapies. Additional trials are needed to elucidate the place of statins for the treatment of psoriasis. A larger follow-up study, as well as testing atorvastatin in patients with more intensive disease characterized by high PASI scores, is needed. Studies using higher atorvastatin doses or dose-ranging studies should also be performed. SN - 1875-9114 UR - https://www.unboundmedicine.com/medline/citation/22026392/Atorvastatin_for_the_treatment_of_plaque_type_psoriasis_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=22026392.ui DB - PRIME DP - Unbound Medicine ER -